RESOLUTE

13 academic and industry partners join forces to unlock the solute carrier class of transporters for effective new therapie

RESOLUTE (Research empowerment on solute carriers), a public-private research partnership supported by the Innovative Medicines Initiative (IMI) with 13 partners from academia and industry, announced the start of a 5-year research project on July 1, 2018. The goal of the project is to intensify worldwide research on solute carriers (SLCs), a relatively understudied group of proteins that control essential physiological functions, and potentially establish them as a novel target class for medicine research and development.

By combining an inclusive, open-access ethos to the techniques and results of the research with the highest-possible quality of research output, RESOLUTE expects to accelerate research in the field of SLCs to the global benefit of both basic academic research and applied research in small biotech and pharmaceutical companies.

The RESOLUTE consortium successfully applied for an IMI grant within the H2020 Programme of the European Union. The project costs will be covered by a €12 million grant under the auspices of the IMI joint undertaking and in-kind contributions from industry partners totalling €11.85 million.

The RESOLUTE consortium includes universities, research institutes, SMEs and European Federation of Pharmaceutical Industries and Associations (EFPIA) members. Project coordination is shared between academia and industry. Giulio Superti-Furga from CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences is the academic coordinator and Claire Steppan, Ph.D., a scientist from Pfizer Inc. is the EFPIA project lead.

Other partner organisations within the consortium are

  • The University of Oxford,
  • The University of Manchester,
  • AXXAM Spa,
  • The Leiden University,
  • The Max Planck Gesellschaft zur Forderung der Wissenschaften eV,
  • The University of Vienna,
  • Novartis Pharma AG,
  • Boehringer Ingelheim International GmbH,
  • VIFOR Pharma Group,
  • Sanofi-Aventis Recherche & Developpement (SARD),
  • and Bayer AG.

 

Read more...